Inflammatory markers, amino-terminal pro-brain natriuretic peptide, and mortality risk in dyspneic patients

American Journal of Clinical Pathology

Volumn 130, Issue 2, 2008, Pages 305-311

  Rehman, Shafiq ^a   Lloyd Jones, Donald M ^b   Martinez Rumayor, Abelardo ^a   Januzzi Jr , James L ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Division of Cardiology   (United States)

Author keywords

Amino terminal pro brain natriuretic peptide; C reactive protein; Dyspnea; Inflammatory markers; Mortality

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; DYSPNEA; HAZARD RATIO; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; STATISTICAL SIGNIFICANCE;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DYSPNEA; HUMANS; INFLAMMATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; RISK;

EID: 48649096465     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/L7BP57F7UF7YNYKX     Document Type: Article

References (30)

1. Januzzi JL Jr, Sakhuja R, O'Donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006;166:315-320.
2. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy: thrombolysis in myocardial infarction. J Am Coll Cardiol. 1998;31:1460-1465.
3. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331:417-424.
4. Inoue N. Vascular C-reactive protein in the pathogenesis of coronary artery disease: role of vascular inflammation and oxidative stress. Cardiovasc Hematol Disord Drug Targets. 2006;6:227-231.
5. Abdellaoui A, Al-Khaffaf H. C-reactive protein (CRP) as a marker in peripheral vascular disease. Eur J Vasc Endovasc Surg. 2007;34:18-22.
6. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174:867-874.
7. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:250-255.
8. Rogowski O, Shapira I, Berliner S, et al. Acute phase response detection and quantitation at the point of care in older adults with acute bacterial infections. J Gerontol A Biol Sci Med Sci. 2005;60:1324-1327.
9. Müller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis. 2007;7:10. doi:10.1186/1471-2334-7-10.
10. Chirinos JA, Zambrano JP, Chakko S, et al. Usefulness of C-reactive protein as an independent predictor of death in patients with ischemic cardiomyopathy. Am J Cardiol. 2005;95:88-90.
11. Anand IS, Latini R, Florea VG, et al; for the Val-HeFT Investigators. C reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation. 2005;112:1428-1434.
12. Windram JD, Loh PH, Rigby AS, et al. Relationship of high-sensitivity C-reactive protein to prognosis and other prognostic markers in outpatients with heart failure. Am Heart J. 2007;153:1048-1055.
13. Mueller C, Laule-Kilian K, Christ A, et al. Inflammation and long term mortality in acute congestive heart failure. Am Heart J. 2006;151:845-850.
14. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol. 2005;95:948-954.
15. Yin WH, Chen JW, Jen HL, et al. Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J. 2004;147:931-938.
16. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-1812.
17. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest. 1993;91:1351-1357.
18. Krack A, Sharma R, Figulla HR, et al. The importance of the gastrointestinal system on the pathogenesis of heart failure. Eur Heart J. 2005;26:2368-2374.
19. Peschel T, Schönauer M, Thiele H, et al. Invasive assessment of bacterial endotoxin and inflammatory cytokines in patients with acute heart failure. Eur J Heart Fail. 2003;5:609-614.
20. Mari D, Di Berardino F, Cugno M. Chronic heart failure and the immune system. Clin Rev Allergy Immunol. 2002;23:325-340.
21. Kubota T, Miyagishima M, Alvarez RJ, et al. Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. J Heart Lung Transplant. 2000;19:819-824.
22. Folkeringa RJ, Van Kraaij DJ, Tieleman RG, et al. Statins associated with reduced mortality in patients admitted for heart failure. J Card Fail. 2006;12:134-138.
23. Foody JM, Shah R, Galusha D, et al. Statins and mortality among elderly patients hospitalized with heart failure. Circulation. 2006;113:1086-1092.
24. Sliwa K, Woodiwiss A, Kone VN, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation. 2004;109:750-755.
25. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602.
26. Chung ES, Packer M, Lo KH, et al; for the Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate to severe heart failure: results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
27. Jialal I, Devaraj S, Singh U. C-reactive protein and the vascular endothelium: implications for plaque instability. J Am Coll Cardiol. 2006;47:1379-1381.
28. Bettencourt P, Azevedo A, Pimenta J, et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110:2168-2174.
29. Dimitrijević O, Stojcevski BD, Ignjatović S, et al. Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome. Int Heart J. 2006;47:833-842.
30. Milo O, Cotter G, Kaluski E, et al. Comparison of inflammatory and neurohormonal activation in cardiogenic pulmonary edema secondary to ischemic versus nonischemic causes. Am J Cardiol. 2003;92:222-226.